| 产品详情 |
| Edit |   |
|---|
| Product Name | Anti-β2 GP-1 screen (Beta 2 Glycoprotein 1) ELISA |
|---|
| Description | The Eagle Biosciences Anti-b2 GP-I Screen ELISA Assay Kit is used for the semi-quantitative determination of IgG, IgM and IgA antibodies to β2 glycoprotein-I in human serum or plasma. The antibodies of the controls and the diluted patient samples react with human β2 GP-I, immobilized on the solid phase of microtiter plates. The use of highly purified β2 GP-I guarantees the specific binding of antibodies to β2 glycoprotein-I of the specimen under investigation. Following an incubation period of 60 min at room temperature, unbound serum components are removed by a wash step.The bound IgG antibodies react specifically with anti-human-IgG, -IgM and -IgA conjugated to horseradish peroxidase (HRP) within the incubation period of 30 min at room temperature (RT). Excessive conjugate is separated from the solid-phase immune complexes by the following wash step.HRP converts the colourless substrate solution of 3,3',5,5'-tetramethyl benzidine (TMB) added into a blue product. The enzyme reaction is stopped by dispensing an acidic solution (H2SO4) into the wells after 15 min at RT turning the solution from blue to yellow.The optical density (OD) of the solution at 450 nm is directly proportional to the amount of specific antibodies bound. The OD values of the unknown patient samples are compared to the OD values of the calibrator. Sample Types: serum, plasma. Range: 10-300 U/mL. Sensitivity: Cut-off. Time: 2.5 hours • APAS is an autoimmune disorder comprising such clinical symptoms like arterial or venous thrombosis, thrombocytopenia and recurrent fetal loss. Primary APAS as well as systemic lupus erythematosus (SLE) are characterized by the appearance of autoantibodies to negatively charged phospholipids (1). Although significance and pathological relevance of phospholipid anti bodies are not completely revealed yet, the detection of several autoantibody specificities is usually applied to the differential diagnosis and follow-up of systemic rheumatic inflammatory diseases. Unlike phospholipid antibodies which occur in some patients having infectious disease, phospholipid antibodies of autoimmune disease patients seem to recognize the relevant phospholipids in association with a plasma protein cofactor. One of these cofactors has been identified as ?2 glycoprotein-I (?2 GP-I) (apo lipo pro tein H) (2,3). ?2 GP-I, a serum protein with a molecular weight of 50 kDa affects platelet aggregation and coagulation. The positively charged fifth domain of ?2 GP-I interacts with negatively charged phospholipids or activated polystyrol surfaces of ELISA wells. This interaction results in conformational changes of ?2 GP-I and the creation of new epitopes apparently recognized by autoimmune phospholipid autoantibodies. |
|---|
| Size | 1 x 96 well |
|---|
| Concentration | n/a |
|---|
| Applications | RUO |
|---|
| Other Names | B2S31-K01 ASSAY EIA ELISA IMMUNOASSAY KIT Anti Beta, glycoprotein I TEST APAS, anti-phospholipid |
|---|
| Gene, Accession, CAS # | n/a |
|---|
| Catalog # | B2S31-K01 |
|---|
| Price | |
|---|
| Order / More Info | Anti-β2 GP-1 screen (Beta 2 Glycoprotein 1) ELISA from EAGLE BIOSCIENCES INC. |
|---|
| Product Specific References | n/a |
|---|
| 产品资料 |
|
|